Industry funds mainly invest in specific industries, and pharmaceutical funds will make 8% of their assets into pharmaceutical stocks. The advantage lies in centralization, and the disadvantage lies in centralization. It belongs to a typical high-risk and high-return category. The ability to select stocks for fund managers is also relatively high. The fund was established shortly, and its current performance is acceptable. The aging society in China will become more and more serious, and the huge demand is enough to support the performance of pharmaceutical companies. Moreover, medicine is an aperiodic industry with anti-inflation properties. There is no problem in the medium and long-term prospects of the industry.

Appropriate participation is recommended. Relatively suitable for fixed investment, share some market risks through fixed investment. One-time purchase requires investors' risk tolerance.